Dezheng Huo to Chemotherapy, Adjuvant
This is a "connection" page, showing publications Dezheng Huo has written about Chemotherapy, Adjuvant.
Connection Strength
0.555
-
Predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer using a machine learning approach. Breast Cancer Res. 2024 Oct 29; 26(1):148.
Score: 0.194
-
Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results. Breast Cancer Res Treat. 2018 Feb; 168(1):207-220.
Score: 0.120
-
Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States. JAMA Oncol. 2017 Jul 01; 3(7):928-935.
Score: 0.117
-
Adjuvant Chemotherapy Use for Hormone Receptor-Positive, ERBB2-Negative Breast Cancer After RxPONDER Trial. JAMA Netw Open. 2025 Dec 01; 8(12):e2549109.
Score: 0.052
-
Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer. 2024 04 15; 130(8):1210-1220.
Score: 0.046
-
Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer. Clin Genitourin Cancer. 2006 Sep; 5(2):150-4.
Score: 0.014
-
Planned post-chemoradiation neck dissection: significance of radiation dose. Laryngoscope. 2006 Jan; 116(1):33-6.
Score: 0.013